Home > Boards > US Listed > Medical - Drugs > Flexion Therapeutics, Inc. (FLXN)

Flexion Therapeutics, Inc. 10 Mall Road Suite 301

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 412
Posts 55,045
Boards Moderated 19
Alias Born 12/16/01
160x600 placeholder
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 11/6/2020 4:30:00 PM
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/5/2020 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2020 4:03:18 PM
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire Inc. - 11/4/2020 4:01:00 PM
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020 GlobeNewswire Inc. - 10/29/2020 4:30:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 7:06:10 AM
Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million GlobeNewswire Inc. - 10/13/2020 6:59:10 AM
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa GlobeNewswire Inc. - 10/8/2020 4:30:10 PM
Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting GlobeNewswire Inc. - 10/5/2020 9:00:10 AM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 10/2/2020 4:30:10 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/21/2020 3:28:12 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 9/11/2020 4:21:53 PM
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference GlobeNewswire Inc. - 9/9/2020 4:30:10 PM
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial GlobeNewswire Inc. - 9/8/2020 4:30:10 PM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 9/4/2020 4:30:10 PM
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire Inc. - 9/3/2020 4:30:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2020 4:48:13 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/20/2020 4:46:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/19/2020 5:01:03 PM
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors GlobeNewswire Inc. - 8/19/2020 9:00:10 AM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/7/2020 4:30:10 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 4:23:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:07:09 PM
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire Inc. - 8/5/2020 4:01:10 PM
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 GlobeNewswire Inc. - 7/30/2020 4:30:10 PM
TREND1 Member Level  Thursday, 03/23/17 02:07:01 PM
Re: None
Post # of 69 
Flexion Therapeutics, Inc. 10 Mall Road Suite 301 Burlington, MA 01803 United States Phone: 781-305-7777 Fax: 781-202-3399 Website: http://www.flexiontherapeutics.com Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences